Sign In
Buy BTMD
biote Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0600 |
| EPS Surprise | -33.33% |
| Revenue estimate | 46.022M |
| Revenue actual | 44.935M |
| Revenue Surprise | -2.36% |
| Release date | Mar 11, 2026 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0600 |
| EPS Surprise | 20.00% |
| Revenue estimate | 45.829M |
| Revenue actual | 46.408M |
| Revenue Surprise | 1.26% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0500 |
| EPS actual | $0.220 |
| EPS Surprise | 340.00% |
| Revenue estimate | 45.79M |
| Revenue actual | 47.956M |
| Revenue Surprise | 4.73% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.100 |
| EPS Surprise | 66.67% |
| Revenue estimate | 47.758M |
| Revenue actual | 48.863M |
| Revenue Surprise | 2.31% |
Last 4 Quarters for biote
Below you can see how BTMD performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $3.86 |
| EPS estimate | $0.0600 |
| EPS actual | $0.100 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $4.07 |
| Aug 01, 2025 | $3.89 |
| Aug 04, 2025 | $4.13 |
| Aug 05, 2025 | $4.17 |
| Aug 06, 2025 | $3.86 |
| Aug 07, 2025 | $2.92 |
| Aug 08, 2025 | $2.88 |
| Aug 11, 2025 | $2.82 |
| Aug 12, 2025 | $2.89 |
| 4 days before | -5.16% |
| 4 days after | -25.13% |
| On release day | -24.35% |
| Change in period | -28.99% |
| Release date | Nov 05, 2025 |
| Price on release | $2.93 |
| EPS estimate | $0.0500 |
| EPS actual | $0.220 |
| EPS surprise | 340.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $2.78 |
| Oct 31, 2025 | $2.87 |
| Nov 03, 2025 | $2.83 |
| Nov 04, 2025 | $2.86 |
| Nov 05, 2025 | $2.93 |
| Nov 06, 2025 | $2.84 |
| Nov 07, 2025 | $2.71 |
| Nov 10, 2025 | $2.46 |
| Nov 11, 2025 | $2.61 |
| 4 days before | 5.40% |
| 4 days after | -11.09% |
| On release day | -3.07% |
| Change in period | -6.29% |
| Release date | Mar 11, 2026 |
| Price on release | $1.72 |
| EPS estimate | $0.0500 |
| EPS actual | $0.0600 |
| EPS surprise | 20.00% |
| Date | Price |
|---|---|
| Mar 05, 2026 | $2.07 |
| Mar 06, 2026 | $1.88 |
| Mar 09, 2026 | $1.79 |
| Mar 10, 2026 | $1.70 |
| Mar 11, 2026 | $1.72 |
| Mar 12, 2026 | $1.54 |
| Mar 13, 2026 | $1.40 |
| Mar 16, 2026 | $1.39 |
| Mar 17, 2026 | $1.36 |
| 4 days before | -16.91% |
| 4 days after | -20.93% |
| On release day | -10.47% |
| Change in period | -34.30% |
| Release date | May 06, 2026 |
| Price on release | $2.20 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0600 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $2.22 |
| May 01, 2026 | $2.19 |
| May 04, 2026 | $2.11 |
| May 05, 2026 | $2.21 |
| May 06, 2026 | $2.20 |
| May 07, 2026 | $2.09 |
| May 08, 2026 | $2.18 |
| May 11, 2026 | $2.21 |
| May 12, 2026 | $2.20 |
| 4 days before | -0.90% |
| 4 days after | 0% |
| On release day | -5.00% |
| Change in period | -0.90% |
biote Earnings Call Transcript Summary of Q1 2026
Biote reported Q1 2026 revenue of $44.9M, down 8.3% year-over-year, driven primarily by a voluntary recall of certain bio-identical hormone pellets that disrupted supply and sales execution. Procedure revenue declined 13.2% to $31.3M, with management estimating a direct recall-related revenue impact of ~$1.7M and incremental costs of ~$1.5M. Dietary supplement revenue grew 19.1% to $11.0M, driven by e-commerce. Gross margin compressed to 68.9% (from 74.3%), partially due to $1.1M of recall-related costs and a temporary increase in third-party supply (Asteria Health mix fell to ~30% of shipments in Q1). Adjusted EBITDA fell to $8.7M (19.4% margin). Cash was $5.3M at quarter-end; operating cash flow was $3.9M. Management completed most of its planned salesforce expansion (to ~120 reps), trained 200+ new practitioners in Q1 (a leading indicator for future procedure and supplement revenue), and is focused on higher-value practitioner targeting and top-clinic retention. Management expects the Asteria supply situation to normalize in the coming weeks and anticipates procedure revenue will return to growth in H2 2026. Company reaffirmed full-year guidance: 2026 revenue above $190M and adjusted EBITDA greater than $38M.
